Sandoz US News


Sandoz announces plans for five major global biosimilar launches by 2020

Holzkirchen, June 20, 2016. Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020, aiming at broadening access to these treatments for more patients. Biosimilars, which are clinically comparable to their reference biologics and introduced following loss of patent exclusivity, represent a significant opportunity for health care savings globally.

Fougera Announces Plans for New State-of-the-Art Facilities

Melville, NY, March 7, 2016 – Fougera Pharmaceuticals Inc. (“Fougera”), a wholly owned subsidiary of Sandoz Inc. (“Sandoz”), operating its PharmaDerm® branded and generic dermatology businesses, has announced plans to consolidate its two production facilities, currently located in Melville and Hicksville, N.Y. The consolidation—which will move all of the company’s operations to the Melville site—is expected to take place during the next four to five years, with a target completion some time in 2020.

Sandoz launches generic version of SKELAXIN® in the US

Princeton, New Jersey, November 19, 2015 – Sandoz today announced the US market re-introduction of metaxalone tablets, a generic version of SKELAXIN® (distributed by Pfizer Inc)1.

Sandoz Careers


Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

 Learn more about a career with Sandoz in the US


Vets Hiring 300

Transitioning to civilian service soon? Consider a career with Sandoz, a Novartis company. Learn about our mission, and why you should explore being a part of our team.




Slideshow Background Images